Unlike Israeli patients, who receive a prescription mainly based on THC and CBD levels, German doctors prescribe their patients specific products and strains, which makes the strategic marketing partnership with Neuraxpharm vital to Panaxia’s future success or failure in the country.
cnxps.cmd.push(function () { cnxps({ playerId: ’36af7c51-0caf-4741-9824-2c941fc6c17b’ }).render(‘4c4d856e0e6f4e3d808bbc1715e132f6’); });
The entrance into the massive German market only furthers the divide between Panaxia and its Israeli competitors, which raises pressure on Israel’s Health Ministry to approve other companies for export, thereby raising Israel’s overall presence in the fast-growing worldwide medical cannabis industry.However, the recent dispersal of Israel’s government, which also left the motion to reclassify CBD as a food additive only a single meeting from approval, may further delay export permits from being issued in the coming months, a move which could entrench Panaxia’s lead in the market.Last week, the company also released its first shipment of samples of medical cannabis tablets and medical cannabis oils to France, as part of a joint bid with Neuraxpharm to participate in a prestigious French government pilot to regulate the country’s medical cannabis industry.
